In the Phase IIIa FRONTIER 2 trial, participants aged 12 years and older who received Mim8 showed a significant and superior reduction in bleeding episodes after treatment.
FRONTIER 2 trial results show promise for Mim8 as potential treatment for hemophilia A
Leave a comment
